BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/22/2026 8:40:58 AM | Browse: 0 | Download: 0
 |
Received |
|
2025-12-28 08:42 |
|
Peer-Review Started |
|
2025-12-28 08:43 |
|
First Decision by Editorial Office Director |
|
2026-02-03 09:44 |
|
Return for Revision |
|
2026-02-03 09:44 |
|
Revised |
|
2026-03-05 12:30 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-04-07 02:44 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-04-07 05:32 |
|
Articles in Press |
|
2026-04-07 05:32 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-06-10 02:24 |
|
Publish the Manuscript Online |
|
2026-06-22 08:40 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Glioblastoma in the post-2021 era: Diagnostic recalibration, therapeutic innovations, and future horizons
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sagar Raut, Sai Kumar Samala and Santosh K Prusty |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Sagar Raut, Assistant Professor, MD, Department of Radiotherapy and Oncology, PGIMER Satellite Centre, Patiala Road, Sangrur 148001, Punjab, India. snraut161@gmail.com |
| Key Words |
Glioblastoma; Chimeric antigen receptor T-cell therapy; Tumor treating fields; Immunotherapy; Radiotherapy, molecular diagnostic techniques |
| Core Tip |
The management of glioblastoma (GBM) has entered a post-2021 era characterized more by convergent advances in molecular classification, trial design, and immunoengineering than by a single therapeutic breakthrough. The 2021 WHO Central Nervous System 5 redefinition of GBM as an isocitrate dehydrogenase-wildtype entity has altered clinical trial interpretation, diagnosis, and prognosis. Molecularly selected targeted therapies, improved Tumor Treating Fields, and a deliberate shift away from ineffective single-agent immunotherapy toward combinatorial and neoadjuvant approaches are driving incremental progress, even though conventional chemoradiation continues to be the cornerstone of care. Locoregionally administered, multivalent engineered cell therapies, along with developments in liquid biopsy, spatial profiling, and adaptive platform trials, provide the most convincing indications of future impact. When taken as a whole, these advancements highlight a move in GBM treatment paradigms toward precision-guided, biologically informed, and adaptive approaches. |
| Publish Date |
2026-06-22 08:40 |
| Citation |
Raut S, Samala SK, Prusty SK. Glioblastoma in the post-2021 era: Diagnostic recalibration, therapeutic innovations, and future horizons. World J Clin Oncol 2026; 17(6): 118209
|
| URL |
https://www.wjgnet.com/2218-4333/full/v17/i6/118209.htm |
| DOI |
https://doi.org/10.5306/wjco.118209 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
